You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
歐康維視生物-B(01477.HK):自主研發I類新藥OT-202在中國的臨牀試驗獲得首例患者入組
格隆匯 01-04 20:42

格隆匯1月4日丨歐康維視生物-B(01477.HK)發佈公吿,OT-202(酪氨酸激酶抑制劑)為公司自主研發治療乾眼症的I類新藥,其單次╱多次給藥在中國健康受試者中的隨機、雙盲、安慰劑對照的安全性、耐受性及藥代動力學特性的臨牀試驗首例患者入組完成。

OT-202(酪氨酸激酶抑制劑)為首款公司自主研發治療乾眼症的I類新靶點新藥。乾眼症的核心機制主要是由於淚流量減少或高蒸發造成的多種因素及疾病,導致眼淚高滲透性。此高滲透狀態激活眼球表面的一系列炎症事件,並將炎症介質釋放到眼淚中,因而使循環持續。乾眼症的關鍵治療是打破炎症的惡性循環。脾酪氨酸激酶(Syk)為一種細胞質蛋白激酶,在多種生物學功能上擔當關鍵角色,包括經典免疫受體,例如激活性Fc受體(FcR)及B細胞受體(BCR)的細胞內信號級聯反應,這對引發炎症特別重要。

Syk抑制劑可用於治療多種過敏性疾病、自身免疫疾病及炎性疾病。Syk為OT-202的作用靶點,OT-202透過抑制Syk激酶的活性達到抗炎作用,在豚鼠免疫型乾眼症模型及小鼠東莨菪礆乾眼症模型中均顯示出顯著的治療及抗炎作用。毒理學研究亦指出其在動物體內具有良好的耐受性。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account